Default company panoramic image


GenSight is a biopharmaceutical company,dedicated to the development of gene therapy based treatments of retinal degenerative diseases

  • Stage Concept Only
  • Industry Biotechnology
  • Location Paris, IDF, France
  • Currency USD

Company Summary

Based on recent results obtained by its scientific founders,the company develops innovative approaches to(i) prevent retinal degeneration in selected pathological conditions and (ii) to restore vision in patients suffering from very low vision or blindness.Its therapeutic projects are drawing upon a very strong expertise in gene transfer into specific retinal cell targets and its ability to transform a standard cell into a light sensitive cell.


  • Default avatar
    Bernard Gilly
    Executive Chaiman

    Bernard Gilly has been Chaiman and CEO of Fovea,a biotech he founded in 2005 and he sold in 2009 to Sanofi.Prior to Fovea, Bernard was a partner at Sofinnova from 2000 to 2005.Prior to joining Sofinnova,Bernard has been President and CEO of Transgene,VP R&D at Pasteur-Merieux-Connaught and he was a member of the Executive Committee

  • Default avatar
    Jean-François Carmier

    Since 2007Jean-François is the owner of BPC PARTNERS,a consultant company for health industries.From 2005 to 2007,he has been Executive Vice President of quality and operations at BioMérieux.In 1996,he joined Transgene as VP of Pharmaceutical Development and became CEO in 2002.Prior to joining Transgene ,he served in various capacities at Pasteur Merieux Connaught.

  • Default avatar
    Nitza Thomasson
    Preclinical Development

    Nitza Thomasson joined the pharmaceutical industry in 2001 and spent 7 years at Servier Pharmaceutical as head of Biological Studies.In 2009,she joined Fovea Pharmaceuticals lo lead the development of compounds in ophtamology.In 2010,sh is assigned Director of Preclinical Department of Sanofi Ophtamology Business.